February 1, 2023. – Toronto, ON: LifeLabs is pleased to share the launch of SignateraTM, a highly sensitive, personalized molecular residual disease assay (MRD) test developed by Natera for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. The first of its kind, this innovative ...

TORONTO, ON. [December 17, 2019] – LifeLabs is releasing the below open letter to its customers in Canada, following a recent cyber security-attack. To our customers: Through proactive surveillance, LifeLabs recently identified a cyber-attack that involved unauthorized access to our computer systems with customer information that could include name, address, ...

LifeLabs Genetics is proud to announce the expansion of our molecular diagnostic testing capabilities. As a result of feedback from healthcare providers across the country who want access to Canadian genetic testing options, we are now offering testing for inherited conditions, using next-generation sequencing, from our lab in Surrey, British ...

Tuberous sclerosis complex is a genetic disorder characterized by the growth of numerous benign tumors in vital organs, such as skin, brain, kidneys among others. Common clinical indications of TSC include, but are not limited to: Skin Patches of white- or light-coloured skin (Hypomelanotic macules) Oval-shaped skin lesions (Shagreen ...